Biological: CAR-T cell immunotherapyMulti-target tumor specific CAR-Ts for CD19 and CD22 in B cell leukemia and lymphoma, CD33 in myeloid leukemia, B-cell maturation antigen (BCMA) and CD38 in multiple myeloma, NY-ESO-1 in multiple myeloma, esophagus cancer, lung cancer, and synovial sarcoma, DR5 in hepatoma, C-met in hepatoma, colorectal cancer, ovarian cancer and renal carcinoma, EGFR V III in hepatoma, lung cancer and glioma, and mesothelin in gastric cancer, pancreatic cancer and mesothelioma. Here, CD19 is linked to esophageal cancer.